該雜志國(guó)際簡(jiǎn)稱(chēng):Eclinicalmedicine,是由出版商Elsevier出版的一本致力于發(fā)布醫(yī)學(xué)研究新成果的的專(zhuān)業(yè)學(xué)術(shù)期刊。該雜志以MEDICINE, GENERAL & INTERNAL研究為重點(diǎn),主要發(fā)表刊登有創(chuàng)見(jiàn)的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報(bào)道階段性研究成果和重要研究工作的最新進(jìn)展,選載對(duì)學(xué)科發(fā)展起指導(dǎo)作用的綜述與專(zhuān)論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有很高的學(xué)術(shù)影響力。
《Eclinicalmedicine》是一本以English為主的開(kāi)放獲取國(guó)際優(yōu)秀期刊,中文名稱(chēng)臨床醫(yī)學(xué),本刊主要出版、報(bào)道醫(yī)學(xué)-MEDICINE, GENERAL & INTERNAL領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專(zhuān)業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專(zhuān)業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為9.6,最新CiteScore 指數(shù)為18.9。
本刊近期中國(guó)學(xué)者發(fā)表的論文主要有:
CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn?s disease: a multicentre cohort study
Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study
Author: Yang, Aimin; Shi, Mai; Lau, Eric S. H.; Wu, Hongjiang; Zhang, Xinge; Fan, Baoqi; Kong, Alice P. S.; Luk, Andrea O. Y.; Ma, Ronald C. W.; Chan, Juliana C. N.; Chow, Elaine
Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: Data from the ATTIRE trial
eClinicalMedicine covers clinical research from all medical specialties—from diagnosis to treatment, prevention to palliative care, and health promotion to health policy and equity. We aim to help frontline health professionals navigate the complex and rapid health transitions facing societies worldwide and aspire to be a catalyst to rethink and reframe the future of health and health care with the ultimate goal of strengthening health systems as core institutions.As a popular journal among medical professionals worldwide, it helps them improve the quality and efficiency of healthcare services by providing the latest medical research findings and clinical practice guidelines.
中科院SCI分區(qū)
Eclinicalmedicine雜志中科院分區(qū)信息
2023年12月升級(jí)版
綜述:否
TOP期刊:是
大類(lèi):醫(yī)學(xué) 1區(qū)
小類(lèi):
MEDICINE, GENERAL & INTERNAL 醫(yī)學(xué):內(nèi)科 1區(qū)
2022年12月升級(jí)版
綜述:否
TOP期刊:是
大類(lèi):醫(yī)學(xué) 1區(qū)
小類(lèi):
MEDICINE, GENERAL & INTERNAL 醫(yī)學(xué):內(nèi)科 1區(qū)
該雜志是一本國(guó)際頂級(jí)雜志,在醫(yī)學(xué)-MEDICINE, GENERAL & INTERNAL學(xué)科領(lǐng)域中屬于核心刊物,是能夠綜合反映該學(xué)科領(lǐng)域當(dāng)前最高發(fā)展水平的學(xué)術(shù)期刊。在國(guó)際上有很高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,該雜志在MEDICINE, GENERAL & INTERNAL綜合專(zhuān)業(yè)領(lǐng)域?qū)I(yè)度認(rèn)可很高,對(duì)稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求非常高,作為一本國(guó)際頂級(jí)雜志,一般投稿過(guò)審時(shí)間都較長(zhǎng),投稿過(guò)審時(shí)間平均 10 Weeks ,如果想投稿該刊要做好時(shí)間安排。版面費(fèi)不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請(qǐng)咨詢(xún)客服。